• HEXO (HEXO) has launched an at-the-market equity program to issue and sell up to US$40,000,000 of common shares
  • The ATM program replaces the previous “at-the-market” offering terminated on April 11, 2022
  • The ATM Program will be effective until June 10, 2023
  • Net proceeds from the ATM Program will be used for working capital
  • HEXO is an award-winning licensed producer of innovative products for the global cannabis market
  • HEXO Corp. (HEXO) opened trading at C$0.51 per share

HEXO (HEXO) has launched an at-the-market equity program to issue and sell up to US$40,000,000 of common shares.

All common shares sold under the ATM Program will be made through the Toronto Stock Exchange, NASDAQ Capital Markets or any other marketplace on which the company’s shares are traded in Canada and the United States.

The ATM program replaces the previous “at-the-market” offering between the company and BMO Nesbitt Burns Inc. as Canadian agent and A.G.P./Alliance Global Partners and BMO Capital Markets Corp. which was terminated effective April 11, 2022.

The volume and timing of distributions under the ATM Program will be determined at the company’s sole discretion. The common shares will be distributed at prevailing market prices.

The ATM Program will be effective until June 10, 2023.

Net proceeds from the ATM Program will be used for working capital and the funding of its operating activities.

HEXO is an award-winning licensed producer of innovative products for the global cannabis market.

HEXO Corp. (HEXO) opened trading at C$0.51 per share.

More From The Market Online

Canopy Growth fuels turnaround story with fresh capital

Canopy Growth (TSX:WEED) continues its turnaround story with a C$96.3 million exchange and subscription deal with an institutional investor.

Junior gold CEO signals conviction with new investment

Cynthia Le Sueur-Aquin, CEO of junior gold stock Laurion Mineral Exploration (TSXV:LME), will exercise 750,000 stock options for C$142,500.

PharmAla Biotech launches educational portal for MDMA

PharmAla Biotech (CSE:MDMA) launches its Prescribers Portal for medical practitioners to learn more about MDMA.